Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
HAWK and HARRIER: 96-Week Outcomes From the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology 2020 Jun 20;[EPub Ahead of Print], PU Dugel, RP Singh, A Koh, Y Ogura, G Weissgerber, K Gedif, GJ Jaffe, R Tadayoni, U Schmidt-Erfurth, FG HolzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.